Phase 2 Study of VX-950, Pegasys and Copegus in Hepatitis C

Vertex Pharmaceuticals

Status and phase: Completed; Phase 2

Conditions: Hepatitis C

Treatments: Drug: VX-950; Drug: ribavirin; Drug: peginterferon alfa-2a

Study type: Interventional

Funder types: Industry

Identifiers

NCT00262483

VX05-950-102

Details and patient eligibility

About

To assess the safety of the combination of VX-950, Pegasys and Copegus in subjects with hepatitis C.

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Infected with hepatitis C virus

Exclusion criteria

• Contraindications to peginterferon or ribavirin therapy.